In an adult dialysis patient with chronic kidney disease and hyperphosphatemia, what iron‑based phosphate binders are recommended, and how should they be dosed and monitored?

Iron-Based Phosphate Binders in Dialysis Patients

Iron-based phosphate binders are effective options for managing hyperphosphatemia in dialysis patients, with two FDA-approved agents available: ferric citrate and sucroferric oxyhydroxide (PA21), both offering the dual benefit of phosphate control and iron supplementation, though with different profiles for anemia management.

Available Iron-Based Phosphate Binders

Ferric Citrate

• Dosing: Start at 1.0-3.0 g/day, typically requiring 2-6 tablets daily 1
• Phosphate-lowering efficacy: Significantly reduces serum phosphate compared to placebo 1
• Anemia benefits: Substantially improves hemoglobin levels, increases ferritin and transferrin saturation, and reduces requirements for both intravenous iron and erythropoiesis-stimulating agents 1
• Additional effects: Reduces serum intact parathyroid hormone (iPTH) levels 1

Sucroferric Oxyhydroxide (PA21)

• Dosing: 1.0-3.0 g/day (2-6 tablets/day), with mean daily use around 4 tablets 2, 3
• Phosphate-lowering efficacy: Non-inferior to sevelamer carbonate in reducing serum phosphate (mean reduction -0.71 mmol/L at 12 weeks), with efficacy maintained over 52 weeks 2, 3
• Pill burden advantage: Requires significantly fewer tablets than sevelamer (average 3 tablets vs. 8 tablets daily), resulting in better adherence (86.2% vs. 76.9%) 2, 3
• Anemia profile: Does NOT significantly increase hemoglobin levels compared to active comparators, despite increasing ferritin 1
• Iron parameters: Mean serum ferritin increases over time, but transferrin saturation, iron, and hemoglobin remain generally stable with no evidence of iron accumulation over 1 year 2

Guideline Framework for Use

The 2017 KDIGO guidelines provide the context for phosphate binder selection 4, 5:

• Treatment initiation: Base decisions on progressively or persistently elevated serum phosphate, not single values 4, 5
• Target: Lower elevated phosphate levels toward the normal range in dialysis patients (CKD G5D) 4
• Binder selection considerations: Account for CKD stage, presence of other CKD-MBD components, concomitant therapies, and side effect profile 4
• Calcium-based binder restriction: Restrict doses of calcium-based phosphate binders, particularly in the presence of arterial calcification, adynamic bone disease, or persistently low PTH 4

Monitoring Requirements

For Ferric Citrate

• Iron metabolic markers: Monitor ferritin and transferrin saturation closely to avoid iron overload 6
• Hemoglobin: Track improvements in anemia parameters 1
• ESA and IV iron requirements: Expect reductions in dosing needs 1

For Sucroferric Oxyhydroxide

• Ferritin levels: Monitor for increases, though iron accumulation has not been demonstrated in long-term studies 2
• Transferrin saturation and hemoglobin: Generally remain stable 2
• Phosphate levels: Maintain within KDIGO target range (1.13-1.78 mmol/L) 2

Side Effect Profile and Management

Common Adverse Events

• Gastrointestinal effects: Both agents cause diarrhea (more frequent with iron-based binders than sevelamer), discolored feces (specific to iron-based binders), and mild transient GI symptoms that typically decrease over time 6, 2, 3
• Withdrawal rates: Sucroferric oxyhydroxide has higher treatment-emergent adverse event withdrawal rates (15.7%) compared to sevelamer (6.6%) 3
• Timing: GI-related adverse events occur early but decrease with continued use 2

Safety Considerations

• Iron overload risk: Ferric citrate requires more vigilant monitoring of iron parameters to prevent overload 6
• Long-term safety: No evidence of iron accumulation with sucroferric oxyhydroxide over 1 year 2
• Cardiovascular outcomes: Long-term data on cardiovascular events and all-cause mortality remain limited for both agents 1

Clinical Decision Algorithm

Choose ferric citrate when:

• Patient has concurrent anemia requiring ESA or IV iron therapy
• Goal is to reduce ESA and IV iron requirements
• Patient can tolerate close monitoring of iron parameters

Choose sucroferric oxyhydroxide when:

• Primary goal is phosphate control with minimal pill burden
• Patient has adherence issues with high tablet counts
• Anemia management is already optimized or not a primary concern
• Concern exists about iron overload risk

Common pitfall: Assuming all iron-based binders provide equivalent anemia benefits—only ferric citrate demonstrates significant hemoglobin improvement and reduction in ESA/IV iron requirements 1